Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Multi-drug Resistant Organisms: MRSA, VRE, and Clostridium difficile (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 106 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Risk Factors and Resistance

Enterococci are largely commensal organisms that are opportunistic pathogens. Underlying disease, an immunocompromised state, age, lengthy hospital stays or long term care, invasive treatments, and/or prior antimicrobial therapy are factors that are associated with significant infections with these species.

As noted previously, enterococci are intrinsically resistant to many antibiotics. Intrinsic resistance affects not only beta lactams (including a broad range of cepahlosporins) and aminoglycosides, but also clindamycin and trimethoprim/sulfamethoxazole. The standard recommended therapy for systemic infections is a combination of either penicillin or vancomycin and an aminoglycoside (gentamicin or streptomycin). The goal of combination therapy is to achieve a synergistic bactericidal effect between the cell wall agent and the aminoglycoside.

In recent decades, increasing resistance to other antibiotics through acquired resistance mechanisms has become a growing therapeutic and infection control problem. Of key concern are high level resistance (HLR) to aminoglycosides and increasing resistance to glycopeptides such as vancomycin.